MC1R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
==== Tubular aggregate myopathy ==== Although tubular aggregates are seen in a variety of myopathies, both genetic and environmental, the congenital myopathies associated with genes STIM1 and ORAI1 are known as tubular aggregate myopathy (TAM) types 1 and 2.
1993/1747) A35 Trunk Road (Tolpuddle to Puddletown Bypass) (Detrunking) Order 1993 (S.I. 1993/1748) Environmental Protection (Prescribed Processes and Substances) (Amendment) Regulations 1993 (S.I. 1993/1749) Northern Ireland Act 1974 (Interim Period Extension) Order 1993 (S.I. 1993/1753) Social Security (Unemployment, Sickness and Invalidity Benefit) Amendment Regulations 1993 (S.I. 1993/1754) Education (School Teachers' Pay and Conditions) (No. 2) Order 1993 (S.I. 1993/1755) Civil Legal Aid (General) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1756) North Circular Trunk Road (A406) and A1400 Trunk Road (Waltham Forest and Redbridge) (Speed Limits) Order 1993 (S.I. 1993/1757) Road Vehicles (Registration and Licensing) (Amendment) Regulations (Northern Ireland) 1993 (S.I. 1993/1759) Road Vehicles (Registration and Licensing) (Amendment) Regulations 1993 (S.I. 1993/1760) Bradford Community Health National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1761) Bradford Hospitals National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1762) Chesterfield and North Derbyshire Royal Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1763) Doncaster Royal Infirmary and Montagu Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1764) Eastbourne and County Healthcare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1765) Northern Devon Healthcare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I.
In chemistry, an ionophore (from Greek ion and -phore 'ion carrier') is a chemical species that reversibly binds ions. Many ionophores are lipid-soluble entities that transport ions across the cell membrane. Ionophores catalyze ion transport across hydrophobic membranes, such as liquid polymeric membranes (carrier-based ion selective electrodes) or lipid bilayers found in the living cells or synthetic vesicles (liposomes). Structurally, an ionophore contains a hydrophilic center and a hydrophobic portion that interacts with the membrane. Some ionophores are synthesized by microorganisms to import ions into their cells. Synthetic ion carriers have also been prepared. Ionophores selective for cations and anions have found many applications in analysis. These compounds have also shown to have various biological effects and a synergistic effect when combined with the ion they bind.
=== Middle East === Palestine: Palestinian Authority president Mahmoud Abbas stated "We will not allow the rights of our people [...] to be infringed on" and affirmed that Gaza is "an integral part of the State of Palestine." Palestinian foreign minister Varsen Aghabekian reiterated the Palestinian Authority's de jure authority over the Gaza Strip, rejected the plan as "unacceptable", and called on other Western countries to do the same. Hamas: Hamas condemned Trump's plan and warned that such a plan would "put oil on the fire in the region". Houthis: Yemeni Houthi authorities released a statement saying that the plan represented "American arrogance" that will subsume all if it is met with "submission from the Arabs". Iran: Iran stated that "Iran does not agree with any displacement of Palestinians and has communicated this through various channels" Saudi Arabia: Saudi Arabia rejected the plan and said that it would "continue its relentless efforts to establish an independent Palestinian state with East Jerusalem as its capital, and will not establish diplomatic relations with Israel without that".
Sources: en.wikipedia.org
Oxymetazoline, sold under the brand name Afrin among others, is a topical decongestant and vasoconstrictor medication. It is available over-the-counter as a nasal spray to treat nasal congestion and nosebleeds, as eye drops to treat eye redness due to minor irritation, and (in the United States) as a prescription topical cream to treat persistent facial redness due to rosacea in adults. Its effects begin within minutes and last for up to six hours. Intranasal use for longer than three to five days may cause congestion to recur or worsen, resulting in physical dependence. Fluticasone propionate (Flonase) and other intranasal glucocorticoids are known to treat oxymetazoline dependence. Oxymetazoline is a derivative of imidazole. It was developed from xylometazoline at Merck by Wolfgang Fruhstorfer and Helmut Müller-Calgan in 1961. A direct sympathomimetic, oxymetazoline binds to and activates α1 adrenergic receptors and α2 adrenergic receptors, most notably. In 2022, it was the 305th most commonly prescribed medication in the United States, with more than 300,000 prescriptions.
==== United States ==== The U.S. Food and Drug Administration (FDA) is the agency responsible for regulation of radiation sources in the United States. Irradiation, as defined by the FDA is a "food additive" as opposed to a food process and therefore falls under the food additive regulations. Each food approved for irradiation has specific guidelines in terms of minimum and maximum dosage as determined safe by the FDA. Packaging materials containing the food processed by irradiation must also undergo approval. The United States Department of Agriculture (USDA) amends these rules for use with meat, poultry, and fresh fruit. The United States Department of Agriculture (USDA) has approved the use of low-level irradiation as an alternative treatment to pesticides for fruits and vegetables that are considered hosts to a number of insect pests, including fruit flies and seed weevils. Under bilateral agreements that allows less-developed countries to earn income through food exports agreements are made to allow them to irradiate fruits and vegetables at low doses to kill insects, so that the food can avoid quarantine. The U.S. Food and Drug Administration and the U.S. Department of Agriculture have approved irradiation of the following foods and purposes:
No intraoperative or postoperative complications were reported, highlighting the procedure's safety profile. CAIRS keratoplasty is particularly advantageous for asymmetric or decentered cones, where customized segment shapes can be tailored to optimize corneal flattening and astigmatism correction. Subsequent studies have validated its efficacy in other types of corneal ectasia, with long-term stability observed up to 5 years. Soosan Jacob holds patents for specialized trephines and devices facilitating CAIRS implantation, further advancing its precision and reproducibility. The ability to customise CAIRS keratoplasty segments to achieve better vision for patients with irregular topography is a huge advantage of the procedure. Some companies have trademarked commercial names for pre-prepared commercial segments such as "CTAK". These procedures are still a CAIRS keratoplasty procedures but the provision of the tissue has been given a brand name for marketing and awareness purposes. An online surgical planning tool has been developed by keratoconus specialists from Brisbane in Australia, Dr Brendan Cronin and Dr David Gunn. This site www.cairsplan.com is free and provides surgeons a tool to assist in planning their CAIRS keratoplasty procedures to enhance outcomes.
=== Pharmacology === Preclinical and early clinical pharmacology studies characterized insulin icodec as a basal insulin analogue. The molecular modifications were intended to create an albumin-bound circulating depot, while preserving insulin receptor-mediated metabolic activity and limiting mitogenic activity relative to human insulin.
(WINNER) The contestant won the whole competition. (WIN) The contestant won "The Killer" (Main Heat challenge). (HIGH) The contestant had one of the best dishes for that week. (IN) The contestant performed well enough to move on to the next week. (LOW) The contestant competed in a Bake Off, but was not eliminated. (LOW) The contestant had one of the bottom dishes for that week, but was not eliminated. (OUT) The contestant competed in a Bake Off and was eliminated for the worst dish. (OUT) The contestant was eliminated for worst dish. ‡The contestant won "The Thriller" (Preheat challenge)
Sources: en.wikipedia.org
== History == Diabulimia is not currently recognised in the DSM-5. Current diagnoses are based on the idea of insulin restriction being a feature of existing anorexia nervosa and bulimia nervosa. Diabulimia is gaining notability within scientific research. In 2019, NHS England began trialling specialist diabulimia clinics. Whilst access to eating disorder clinics is improving, access to specialist diabulimia services is not widely available.
== Function == Osteocalcin is secreted solely by osteoblasts and is thought to play a role in the body's metabolic regulation. In its carboxylated form, calcium is bound directly to the bone and thus concentrates here. In its uncarboxylated form, osteocalcin acts as a hormone in the body, signalling in the pancreas, fat, muscle, testes, and brain.
anxiety changes in vision cloudy urine coughing up blood delirium or hallucinations difficult urination difficulty swallowing dry eyes, mouth, nose, or throat As with any other general anesthetic agent, propofol should be administered only where appropriately trained staff and facilities for monitoring are available, with proper airway management, a supply of supplemental oxygen, artificial ventilation, and cardiovascular resuscitation. Because of propofol's formulation (using lecithin and soybean oil), it is prone to bacterial contamination, despite the presence of the bacterial inhibitor benzyl alcohol; consequently, some hospital facilities require the IV tubing (for continuous propofol infusions) to be changed after 12 hours. This is a preventive measure against microbial growth and potential infection.
=== Natural non-canonical bases === In a cell, there are several non-canonical bases present: CpG islands in DNA (often methylated), all eukaryotic mRNA (capped with a methyl-7-guanosine), and several bases of rRNAs (methylated). Often, tRNAs are heavily modified postranscriptionally in order to improve their conformation or base pairing, in particular in or near the anticodon: inosine can base pair with C, U, and even with A, whereas thiouridine (with A) is more specific than uracil (with a purine). Other common tRNA base modifications are pseudouridine (which gives its name to the TΨC loop), dihydrouridine (which does not stack as it is not aromatic), queuosine, wyosine, and so forth. Nevertheless, these are all modifications to normal bases and are not placed by a polymerase.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.